34 related articles for article (PubMed ID: 17515747)
1. A Prospective Study Comparing the Role of 18 FDG PET-CT with Contrast-Enhanced Computed Tomography and Tc99m Bone Scan for Staging Locally Advanced Breast Cancer.
Bhoriwal S; Deo SVS; Kumar R; Thulkar S; Gogia A; Sharma DN; Mathur S
Indian J Surg Oncol; 2021 Jun; 12(2):266-271. PubMed ID: 34295069
[TBL] [Abstract][Full Text] [Related]
2. Practice and prospects for PET/CT guided interventions.
Bogoni M; Cerci JJ; Cornelis FH; Nanni C; Tabacchi E; SchÖder H; Shyn PB; Sofocleous CT; Solomon SB; Kirov AS
Q J Nucl Med Mol Imaging; 2021 Mar; 65(1):20-31. PubMed ID: 33494585
[TBL] [Abstract][Full Text] [Related]
3. Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase.
Di Gioia D; Stieber P; Schmidt GP; Nagel D; Heinemann V; Baur-Melnyk A
Br J Cancer; 2015 Mar; 112(5):809-18. PubMed ID: 25647014
[TBL] [Abstract][Full Text] [Related]
4. Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.
Cornelis F; Silk M; Schoder H; Takaki H; Durack JC; Erinjeri JP; Sofocleous CT; Siegelbaum RH; Maybody M; Solomon SB
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2265-72. PubMed ID: 25106463
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies.
Werner MK; Aschoff P; Reimold M; Pfannenberg C
Br J Radiol; 2011 Mar; 84(999):e65-7. PubMed ID: 21325361
[TBL] [Abstract][Full Text] [Related]
6. Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.
Eubank WB; Lee JH; Mankoff DA
PET Clin; 2009 Jul; 4(3):299-312. PubMed ID: 20161481
[No Abstract] [Full Text] [Related]
7. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis.
Pan L; Han Y; Sun X; Liu J; Gang H
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1007-22. PubMed ID: 20091186
[TBL] [Abstract][Full Text] [Related]
8. PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences.
Klaeser B; Mueller MD; Schmid RA; Guevara C; Krause T; Wiskirchen J
Eur Radiol; 2009 Jul; 19(7):1780-5. PubMed ID: 19238391
[TBL] [Abstract][Full Text] [Related]
9. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
Groheux D; Cochet A; Humbert O; Alberini JL; Hindié E; Mankoff D
J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity, Specificity and the Diagnostic Accuracy of PET/CT for Axillary Staging in Patients With Stage I-III Cancer: A Systematic Review of The Literature.
Kasem J; Wazir U; Mokbel K
In Vivo; 2021; 35(1):23-30. PubMed ID: 33402446
[TBL] [Abstract][Full Text] [Related]
11. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.
Piperkova E; Raphael B; Altinyay ME; Castellon I; Libes R; Sandella N; Heiba S; Abdel-Dayem H
Clin Nucl Med; 2007 Jun; 32(6):429-34. PubMed ID: 17515747
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
13. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
14. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
15. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
